home / stock / nrbo / nrbo articles
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while ...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, ...
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's session wi...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to ...